REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Rhea-AI Summary
Jaguar Health has announced an upcoming investor webcast on April 30, 2025, at 8:30 AM Eastern to present initial results from a proof-of-concept study of crofelemer. The study focuses on two rare diseases: Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF).
The data was recently presented by Dr. Mohamad Miqdady at the 11th Annual ELITE PED-GI Congress in Abu Dhabi. The webcast will cover:
- Patient experience with MVID and SBS-IF
- Impact of crofelemer on disease progression
- Quality of life improvements
- Potential expedited regulatory pathways for MVID treatment
Notably, MVID is an ultrarare pediatric condition characterized by severe diarrhea and malabsorption, currently with no approved drug treatments. The study utilizes a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug.
Positive
- Potential first-mover advantage as there are currently no approved drug treatments for MVID
- Study results presented by recognized leader in pediatric gastroenterology Dr. Mohamad Miqdady
- Novel liquid formulation of crofelemer being tested for two rare diseases (MVID and SBS-IF)
- Possible expedited regulatory pathways for crofelemer in MVID treatment
Negative
- Still in proof-of-concept phase, indicating early stage of development
- Results are from an investigator-initiated trial, not a company-sponsored pivotal study
- Actual efficacy data and trial results not disclosed in the press release
News Market Reaction
On the day this news was published, JAGX gained 2.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study
SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today issued a reminder that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates.
Participation Instructions for Jaguar Investor Webcast
When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time
Where: Online
Registration link for conference: Click Here
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health/
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company will host an investor webcast on April 30, 2025. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the initial results of Jaguar Health's (JAGX) crofelemer study for MVID and SBS-IF?
What is MVID and why is Jaguar Health's (JAGX) crofelemer study significant?
When and where can investors join Jaguar Health's (JAGX) crofelemer study webcast?
What medical conditions does Jaguar Health's (JAGX) crofelemer target?
Who presented Jaguar Health's (JAGX) crofelemer study results at the ELITE PED-GI Congress?
